The Medicines Co Sells CV Products To Fund Pipeline
The Medicines Co. is selling off three cardiovascular products to Italy's Chiesi Farmaceutici SPA in an effort to raise funds to pay for R&D as top-seller Angiomax continues to decline.
You may also be interested in...
The company Novartis is buying for $9.7bn is largely unrecognizable from the one Clive Meanwell started in 1996, grew into a multi-product hospital specialist and began to sunset in 2015 with the loss of Angiomax.
CEO Clive Meanwell helped to shape the company over his nearly 22 years at the helm, including when it marketed a portfolio of hospital-based drugs. Now the company is solely focused on shepherding the PCSK9 inhibitor inclisiran to the finish line.
The antibiotic Vabomere demonstrated statistical superiority over Zosyn, and could be a more attractive option than existing treatments for complicated urinary tract infections.